GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » 5-Year ROIIC %

NWBO (Northwest Biotherapeutics) 5-Year ROIIC % : 238.43% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Northwest Biotherapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was 238.43%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Northwest Biotherapeutics's 5-Year ROIIC % or its related term are showing as below:

NWBO's 5-Year ROIIC % is ranked better than
88.94% of 1302 companies
in the Biotechnology industry
Industry Median: -22.27 vs NWBO: 238.43

Northwest Biotherapeutics 5-Year ROIIC % Historical Data

The historical data trend for Northwest Biotherapeutics's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics 5-Year ROIIC % Chart

Northwest Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -124.83 13.50 50.44 -260.21 238.43

Northwest Biotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 238.43 - - -

Competitive Comparison of Northwest Biotherapeutics's 5-Year ROIIC %

For the Biotechnology subindustry, Northwest Biotherapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's 5-Year ROIIC % falls into.



Northwest Biotherapeutics 5-Year ROIIC % Calculation

Northwest Biotherapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -55.508 (Dec. 2023) - -44.757 (Dec. 2018) )/( 45.968 (Dec. 2023) - 50.477 (Dec. 2018) )
=-10.751/-4.509
=238.43%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Northwest Biotherapeutics  (OTCPK:NWBO) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Northwest Biotherapeutics 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Northwest Biotherapeutics Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Executives
Navid Malik director 1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch officer: Chief Technical Officer 22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton director, officer: Chief Scientific Officer 22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman officer: See Remarks C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers director, 10 percent owner, officer: President and CEO 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski director C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis officer: See Remarks 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh director WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer director 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp 10 percent owner 27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund 10 percent owner C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc. 10 percent owner 7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer director 10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr. 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814

Northwest Biotherapeutics Headlines

From GuruFocus